Synlogic: Probiotic Enzyme

Synlogic_Logo-Light-Blue (10)

Synlogic Therapeutics is in the process of developing a Synthetic Biotic™ medicine for patients with CBS Deficiency Homocystinuria. To learn more about what this means, click here

March 20, 2023

Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting

  • Presentations included full data from both the Phase 2 Synpheny-1 Study in PKU and Phase 1 Study for SYNB1353 as a potential treatment for HCU

January 05, 2023

Synlogic Provides Corporate Update and Outlook for 2023

  • Pivotal Phase 3 for SYNB1934 in phenylketonuria (PKU) to initiate in H1 2023
  • Rare Pediatric Disease Designation received for SYNB1353 for homocystinuria (HCU)
  • Cash runway expected into H2 2024

November 30, 2022

Synlogic SYNB1353 Phase 1 Top-line Results (Investor Presentation)

November 30, 2022

Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update

  • Top-line Phase 1 data in healthy volunteers show that SYNB1353 reduces plasma methionine by consuming methionine in the GI tract
  • SYNB1353 has been granted Orphan Drug Designation (ODD) from the FDA for the treatment of homocystinuria (HCU)
  • The company confirms expectations for proof-of-concept data for SYNB8802 in enteric hyperoxaluria before year-end and Phase 3 initiation of SYNB1934 for PKU in H1 2023

July 12, 2022

Synlogic Initiates Phase 1 Study of SYNB1353 for the Treatment of Classical HCU

  • Synlogic Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria (HCU)
  • Company expects data from the SYNB1353 healthy volunteer study in H2 2022
  • Trial marks Synlogic’s third clinical-stage program; data readouts for all programs expected in H2 2022